{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-336462","form_type":"8-K","ticker":"GENB","cik":"0002100782","company_name":"Generate Biomedicines, Inc.","filed_at":"2026-08-06T10:00:47+00:00","discovered_at":"2026-08-06T10:10:00.467233+00:00","generated_at":"2026-08-06T10:11:56.404411+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Generate Biomedicines Q2 net loss $67.3M; Phase 3 asthma studies advancing, cash $457.4M","bullets":["Revenue $6.3M (down from $10.1M YoY); net loss $67.3M vs $56.7M YoY; cash $457.4M (down from $516.6M Q1).","Phase 3 SOLAIRIA-1/2 for GB-0895 (anti-TSLP) in severe asthma recruiting in 33 countries; Phase 1b COPD data at ERS Sept 8.","Phase 1 for GB-4362 (MMAE neutralizer) dosed first cohort; FDA Fast Track for urothelial cancer toxicity reduction.","Novartis advanced a biologic designed with Generate's platform into preclinical pipeline; first AI-enabled biologic to reach this stage.","GB-5267 CAR T Phase 1 recruiting for ovarian cancer; first patient expected in 2026; cash runway into H1 2028."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-336462","json":"https://secwatch.observer/filing/0001193125-26-336462.json","markdown":"https://secwatch.observer/filing/0001193125-26-336462.md","text":"https://secwatch.observer/filing/0001193125-26-336462.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2100782/000119312526336462/0001193125-26-336462-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2100782/000119312526336462/ck0002100782-20260806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-06T10:11:56.404411+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}